Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials-Reference-Cited by-同舟云学术

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials

Published:2020-06 Issue:6 Volume:7 Page:e447-e455
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Usmani Saad Z,Nahi Hareth,Plesner Torben,Weiss Brendan M,Bahlis Nizar J,Belch Andrew,Voorhees Peter M,Laubach Jacob P,van de Donk Niels W C J,Ahmadi Tahamtan,Uhlar Clarissa M,Wang Jianping,Feng Huaibao,Qi Ming,Richardson Paul G,Lonial Sagar

Publisher

Elsevier BV

Subject

Hematology

Reference34 articles.

1. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States;Costa;Blood Adv,2017

2. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma;Siegel;J Clin Oncol,2018

3. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial;Dimopoulos;Lancet Oncol,2017

4. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma;Moreau;N Engl J Med,2016

5. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study;Kumar;Leukemia,2012

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells;Nature Cancer;2024-09-11

2. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study;Annals of Hematology;2024-09-04

3. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma;Current Medical Research and Opinion;2024-09-03

4. Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma;Cancers;2024-08-23

5. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study;Blood;2024-08-08